All Photos(1)
Synonym(s):
4-(4-Cyano-2-(2-(4-fluoronaphthalen-1-yl)propanamido)phenyl)butanoic acid, 4-Cyano-2-[[2-(4-fluoro-1-naphthalenyl)-1-oxopropyl]amino]benzenebutanoic acid, AE3-208
Empirical Formula (Hill Notation):
C24H21FN2O3
CAS Number:
Molecular Weight:
404.43
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
CC(C1=C(C=CC=C2)C2=C(F)C=C1)C(NC3=CC(C#N)=CC=C3CCCC(O)=O)=O
InChI
1S/C24H21FN2O3/c1-15(18-11-12-21(25)20-7-3-2-6-19(18)20)24(30)27-22-13-16(14-26)9-10-17(22)5-4-8-23(28)29/h2-3,6-7,9-13,15H,4-5,8H2,1H3,(H,27,30)(H,28,29)
InChI key
MTDIMKNAJUQTIO-UHFFFAOYSA-N
Biochem/physiol Actions
ONO-AE3-208 is an orally active prostaglandin E2 receptor 4 (EP4)-selective antagonist (Ki in nM = 1.3/EP4, 30/EP3, 790/FP and 2400/TP; Ki >10 μM for prostanoid receptors DP, EP1, EP2, IP). Both EP4-/- mice and ONO-AE3-208-treated wild-type mice (10 mg/kg/day in drinking water) are shown to develop severe symptoms (diarrhea, hemoccult, weight loss) in a murine model of DSS-induced colitis. ONO-AE3-208 is also reported to promote ductus arteriosus constriction among fetal and neonatal rats in vivo (10 mg/kg administered orogastrically). In addition, ONO-AE3-208 is demonstrated to effectively inhibit 1 ng/mL IL-1β-induced HUVEC migration in vitro (53% and 75% inhibition by 1 or 10 μM AE3-208, repectively) and block IL-1β (30 ng/Hydron pellet implant)-induced angionesis in mouse corneas in vivo (1 mg/kg/day p.o.).
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Karina Thieme et al.
Scientific reports, 7(1), 3442-3442 (2017-06-15)
The therapeutic targeting of prostanoid subtype receptors may slow the development of chronic kidney disease (CKD) through mechanisms that are distinct from those of upstream COX inhibition. Here, employing multiple experimental models of CKD, we studied the effects of inhibition
Kenta Watanabe et al.
Biochemical and biophysical research communications, 478(1), 154-161 (2016-07-28)
The metastasis of tumors to bone is known to be promoted by prostaglandin E2 (PGE2) produced by the tumor host stromal tissue. Although bone metastases frequently occur in prostate cancer patients, the significance of PGE2 in stromal responses to the
Takashi Kuwano et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 18(2), 300-310 (2004-02-11)
Cyclooxygenase1 (COX1) and COX2 mediate the rate-limiting step in arachidonic acid metabolism. Expression of COX2 mRNA and protein is often enhanced in various human cell types by inflammatory cytokines such as interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha). IL-1beta
Yaqun Wang et al.
Molecular medicine reports, 16(1), 639-646 (2017-06-01)
Recently, certain studies have demonstrated in vitro that prostaglandin E2 (PGE2) promotes human cluster of differentiation (CD)34+ cell homing. However, the sub‑type receptors activated by PGE2 are unknown, as the PGE2 receptor EP1-4 subtypes (EP1-4) are expressed on the membrane of
Kazuo Momma et al.
Pediatric research, 58(5), 971-975 (2005-11-01)
Indomethacin is used to constrict the patent ductus arteriosus in premature infants. To clarify possible prostanoid receptor antagonists that can constrict the ductus, we studied in vivo constriction of the fetal and neonatal ductus arteriosus by AE3-208, a prostanoid EP4-receptor
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service